Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ZNF263 Double Nickase Plasmid (h): sc-411418-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ZNF263 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ZNF263 Double Nickase Plasmid (h) and ZNF263 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ZNF263. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ZNF263 Antibody (8-YD33): sc-135612
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZNF263 Double Nickase Plasmid (h) | sc-411418-NIC | 20 µg | $410.00 | |||
ZNF263 Double Nickase Plasmid (h2) | sc-411418-NIC-2 | 20 µg | $410.00 |
ZNF263 encodes a KRAB domain–containing C2H2 zinc-finger transcription factor that binds specific DNA motifs to regulate gene expression programs linked to chromatin organization and transcriptional repression. Through interactions with KRAB-associated corepressor machinery and epigenetic modifiers, ZNF263 contributes to control of promoter and enhancer activity, influencing cell-cycle progression, differentiation, and genome stability. Altered ZNF263 activity or dysregulated expression has been associated with transcriptional rewiring observed in multiple disease contexts, including cancer-related pathways and aberrant developmental regulation. As a sequence-specific regulator, ZNF263 is frequently investigated to map regulatory networks, identify direct genomic targets, and study mechanisms of epigenetic control.
ZNF263 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ZNF263 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ZNF263. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ZNF263 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ZNF263-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.